A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome

Trial Profile

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Hereditary nephritis; Renal failure
  • Focus Registrational; Therapeutic Use
  • Acronyms CARDINAL
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 25 Sep 2017 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.
    • 25 Sep 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Dec 2019.
    • 14 Aug 2017 According to a Reata Pharmaceuticals media release, one year data from the study are expected to be available during the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top